Novartis Phase Ii Open-Label Extension Orion-3 Trial Of Leqvio Provides Effective Ldl-C Reduction Over Four-Year Period
Novartis Announced Results From The Phase Ii Open-Label Extension Orion-3 Trial, Which Showed That Leqvio Provides Effective Low-Density Lipoprotein Cholesterol (Ldl-C) Reduction Over A Four-Year Period In Patients With Either Atherosclerotic Cardiovascular Disease (Ascvd) Or Ascvd Risk Equivalent, And Elevated Ldl-C Despite Maximally Tolerated Statin Therapy. Leqvio Is The First And Only Small Interfering Rna (Sirna) Therapy To Lower Ldl-C And Is Administered With Two Doses A Year. Results Were Presented At The American Heart Association (Aha) Scientific Sessions 2022.
Optimize Your trial insights with Clival Database.
Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.
With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.
To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.
Elevate your trial success rate with the cutting-edge insights from Clival database.
Check it out today and make more informed sourcing decisions! Learn More!
